Market Research Logo

Dyskinesia - Pipeline Review, H2 2015

Dyskinesia - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Dyskinesia - Pipeline Review, H2 2015’, provides an overview of the Dyskinesia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Dyskinesia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Dyskinesia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Dyskinesia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Dyskinesia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Dyskinesia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Dyskinesia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Dyskinesia Overview
Therapeutics Development
Pipeline Products for Dyskinesia - Overview
Pipeline Products for Dyskinesia - Comparative Analysis
Dyskinesia - Therapeutics under Development by Companies
Dyskinesia - Therapeutics under Investigation by Universities/Institutes
Dyskinesia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Dyskinesia - Products under Development by Companies
Dyskinesia - Products under Investigation by Universities/Institutes
Dyskinesia - Companies Involved in Therapeutics Development
Adamas Pharmaceuticals, Inc.
Addex Therapeutics Ltd
Advicenne Pharma
Amarantus Bioscience Holdings, Inc.
Astraea Therapeutics, LLC
BioMarin Pharmaceutical Inc.
Catalyst Biosciences, Inc.
Catalyst Pharmaceutical Partners, Inc.
Cerecor Inc.
Contera Pharma ApS
EpiVax, Inc.
Heptares Therapeutics Limited
Hua Medicine Ltd.
Integrative Research Laboratories Sweden AB
Ipsen S.A.
Medy-Tox Inc.
Merz Pharmaceuticals GmbH
MitoDys Therapeutics Limited
Neurim Pharmaceuticals Ltd
Neurocrine Biosciences, Inc.
Neurolixis Inc.
Osmotica Pharmaceutical Corp.
Otsuka Holdings Co., Ltd.
Revance Therapeutics, Inc.
Santhera Pharmaceuticals Holding AG
SciFluor Life Sciences, LLC
Synchroneuron Inc.
Teva Pharmaceutical Industries Limited
Dyskinesia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(dextromethorphan hydrobromide + quinidine sulfate) - Drug Profile
A2M-13677 - Drug Profile
abobotulinumtoxin A - Drug Profile
abobotulinumtoxin A next generation - Drug Profile
acamprosate calcium SR - Drug Profile
amantadine hydrochloride ER - Drug Profile
amantadine hydrochloride ER - Drug Profile
AT-127 - Drug Profile
AT-326 - Drug Profile
AT-403 - Drug Profile
befiradol - Drug Profile
CERC-406 - Drug Profile
CPP-115 - Drug Profile
dipraglurant ER - Drug Profile
dipraglurant IR - Drug Profile
Drugs for Dyskinesia - Drug Profile
Drugs for Tardive Dyskinesia - Drug Profile
dutetrabenazine ER - Drug Profile
eltoprazine - Drug Profile
fipamezole - Drug Profile
HTL-14242 - Drug Profile
IRL-790 - Drug Profile
JM-010 - Drug Profile
MLR-1019 - Drug Profile
MRZ-8676 - Drug Profile
Neu-120 - Drug Profile
Neu-240 - Drug Profile
onabotulinumtoxin A - Drug Profile
onabotulinumtoxin A - Drug Profile
PEUN-3 - Drug Profile
RG-2833 - Drug Profile
RT-002 - Drug Profile
SK-609 - Drug Profile
Small Molecule for Dyskinesia - Drug Profile
Small Molecule for Dyskinesia and Hyperkinesia - Drug Profile
Small Molecules for Neurodegenerative Disease - Drug Profile
Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile
Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile
Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile
TC-8831 - Drug Profile
tetrabenazine - Drug Profile
valbenazine - Drug Profile
VU-0431316 - Drug Profile
Dyskinesia - Recent Pipeline Updates
Dyskinesia - Dormant Projects
Dyskinesia - Discontinued Products
Dyskinesia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Dyskinesia, H2 2015
Number of Products under Development for Dyskinesia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015
Dyskinesia - Pipeline by Adamas Pharmaceuticals, Inc., H2 2015
Dyskinesia - Pipeline by Addex Therapeutics Ltd, H2 2015
Dyskinesia - Pipeline by Advicenne Pharma, H2 2015
Dyskinesia - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2015
Dyskinesia - Pipeline by Astraea Therapeutics, LLC, H2 2015
Dyskinesia - Pipeline by BioMarin Pharmaceutical Inc., H2 2015
Dyskinesia - Pipeline by Catalyst Biosciences, Inc., H2 2015
Dyskinesia - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2015
Dyskinesia - Pipeline by Cerecor Inc., H2 2015
Dyskinesia - Pipeline by Contera Pharma ApS, H2 2015
Dyskinesia - Pipeline by EpiVax, Inc., H2 2015
Dyskinesia - Pipeline by Heptares Therapeutics Limited, H2 2015
Dyskinesia - Pipeline by Hua Medicine Ltd., H2 2015
Dyskinesia - Pipeline by Integrative Research Laboratories Sweden AB, H2 2015
Dyskinesia - Pipeline by Ipsen S.A., H2 2015
Dyskinesia - Pipeline by Medy-Tox Inc., H2 2015
Dyskinesia - Pipeline by Merz Pharmaceuticals GmbH, H2 2015
Dyskinesia - Pipeline by MitoDys Therapeutics Limited, H2 2015
Dyskinesia - Pipeline by Neurim Pharmaceuticals Ltd, H2 2015
Dyskinesia - Pipeline by Neurocrine Biosciences, Inc., H2 2015
Dyskinesia - Pipeline by Neurolixis Inc., H2 2015
Dyskinesia - Pipeline by Osmotica Pharmaceutical Corp., H2 2015
Dyskinesia - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
Dyskinesia - Pipeline by Revance Therapeutics, Inc., H2 2015
Dyskinesia - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2015
Dyskinesia - Pipeline by SciFluor Life Sciences, LLC, H2 2015
Dyskinesia - Pipeline by Synchroneuron Inc., H2 2015
Dyskinesia - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Dyskinesia Therapeutics - Recent Pipeline Updates, H2 2015
Dyskinesia - Dormant Projects, H2 2015
Dyskinesia - Dormant Projects (Contd..1), H2 2015
Dyskinesia - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Dyskinesia, H2 2015
Number of Products under Development for Dyskinesia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report